Heron Therapeutics (HRTX) Net Cash Flow (2016 - 2025)
Historic Net Cash Flow for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $26.6 million.
- Heron Therapeutics' Net Cash Flow rose 26100.61% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 29003.07%. This contributed to the annual value of -$2.9 million for FY2024, which is 12159.54% down from last year.
- According to the latest figures from Q3 2025, Heron Therapeutics' Net Cash Flow is $26.6 million, which was up 26100.61% from -$2.8 million recorded in Q2 2025.
- Heron Therapeutics' Net Cash Flow's 5-year high stood at $131.4 million during Q2 2021, with a 5-year trough of -$69.0 million in Q4 2021.
- Its 5-year average for Net Cash Flow is -$3.3 million, with a median of -$6.2 million in 2023.
- In the last 5 years, Heron Therapeutics' Net Cash Flow tumbled by 79049.71% in 2021 and then surged by 106987.42% in 2023.
- Quarter analysis of 5 years shows Heron Therapeutics' Net Cash Flow stood at -$69.0 million in 2021, then soared by 49.19% to -$35.1 million in 2022, then skyrocketed by 82.37% to -$6.2 million in 2023, then soared by 100.99% to $61000.0 in 2024, then skyrocketed by 43427.87% to $26.6 million in 2025.
- Its Net Cash Flow was $26.6 million in Q3 2025, compared to -$2.8 million in Q2 2025 and -$6.5 million in Q1 2025.